Josias Pontes - Feb 28, 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc. (SGTX)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Matthew Kowalsky, Attorney-in-Fact
Stock symbol
SGTX
Transactions as of
Feb 28, 2023
Transactions value $
$0
Form type
4
Date filed
3/1/2023, 03:41 PM
Previous filing
Feb 22, 2022
Next filing
Jul 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGTX Stock Option (Right to Buy) Award $0 +140K $0.00 140K Feb 28, 2023 Common Stock 140K $1.09 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested.